ETHK Labs Inc. Issues Supplementary Announcement on Dual-Platform Nipah Virus Detection Solution

Key Points for Investors and Shareholders

• ETHK Labs Inc. (formerly IVD Medical Holding Limited) has released a supplementary announcement providing detailed updates on the regulatory status and business progress of its newly developed dual-platform solution for Nipah virus detection.
• The solution is developed by subsidiary Shenzhen ICXIVD Biotechnology Co., Ltd. (ICXIVD), utilizing two technical pathways:
  • Intelligent Fluorescent PCR Nucleic Acid Detection Kit (currently ‘Research Use Only’ in China)
  • Metagenomic Next-Generation Sequencing (mNGS) Testing Services (delivered via Laboratory Developed Test model)
• Regulatory and commercial strategies differ for each pathway, with implications for market entry, revenue potential, and risk exposure.
• Integration with AI and national medical informatisation platforms is underway, positioning ETHK Labs for leadership in public health response and diagnostics.
• Ongoing acquisition of B-Soft Co., Ltd. is expected to significantly enhance the company’s ecosystem and market reach.

Detailed Business and Regulatory Update

1. Regulatory Classification & Application Scenarios

Intelligent Fluorescent PCR Nucleic Acid Detection Kit:

• This kit is currently classified as Research Use Only (RUO) in Mainland China, intended mainly for use by customs authorities and disease control centres.
• For clinical use in hospitals, it would require a Class III medical device registration certificate from the China NMPA.
• Crucially, since there have been no cases of Nipah virus infection reported in Mainland China, clinical trial conditions required for registration are not available, and there is currently no timeline for NMPA submission.
• Under existing regulations, use by professional institutions does not require NMPA registration. This allows for immediate market application in statutory monitoring and screening without regulatory delay.

Metagenomic Next-Generation Sequencing (mNGS) Testing Services:

• Delivered primarily through the LDT model (Laboratory Developed Test).
• Since 2022, ICXIVD has provided these services to clinicians by partnering with medical institutions and accepting commissioned tests from third-party labs.
• This business model does not require NMPA registration under current regulatory policies, enabling rapid deployment and commercialization.

2. Business Progress and Technology Maturity

• The mNGS testing service is a mature business line with ongoing market activity, offering closed-loop capabilities from sample processing to high-throughput sequencing and AI-driven analysis.
• The Fluorescent PCR Kit prototype is developed; mass production and deployment will be adjusted according to actual demand from customs and disease control agencies.
• ICXIVD’s core team leverages extensive expertise in genomics, bioinformatics, and AI algorithms, supported by a proprietary AI primer design platform and a localized pathogen database (covering over 18,000 pathogens).
• This enables rapid response for novel pathogen detection, positioning ETHK Labs as a technology leader in public health defense.

3. Ecosystem Synergy and Strategic Integration

• ETHK Labs is accelerating integration of healthcare informatisation, IVD distribution network, and AI ecosystem, particularly through its ongoing acquisition of B-Soft Co., Ltd. (300451.SZ).
• Future plans include integration of ICXIVD’s testing with B-Soft’s BsoftGPT medical big model and syndrome monitoring system, covering nearly 7,000 medical institutions nationwide.
• This will enable a transition from passive detection to a closed-loop system of proactive early warning, precise diagnosis, and intelligent intervention—potentially transforming public health resilience in China.
• ETHK Labs aims to contribute to the “Healthy China” initiative and become a reliable technology partner in global public health security.

4. Risk Factors and Shareholder Considerations

• Market demand for Nipah virus detection products is highly dependent on pandemic evolution, policy direction, and regulatory changes.
• If the Fluorescent PCR Kit enters the hospital clinical market, NMPA registration will be mandatory, potentially affecting commercialization timelines.
• The company has no established timeline for NMPA submission due to lack of clinical cases, which may limit short-term revenue potential.
• Shareholders are advised to exercise caution and note the risks disclosed in both this and previous announcements. These factors could materially affect share values if there are changes in regulatory environment, pandemic severity, or policy direction.

Board and Leadership

The Board currently comprises seven directors, including two executive directors (Mr. Lin Xianya, Mr. Chan Siu Kei Ken), two nonexecutive directors (Ms. Yao Haiyun, Mr. Liu Fei), and three independent nonexecutive directors (Dr. Zhong Renqian, Mr. Xu Da, Mr. Zhang Jianlei).

Conclusion

ETHK Labs Inc.’s rapid development of dual-platform Nipah virus detection technology and integration with national health informatisation and AI platforms signal a strategic move that could drive future growth and significantly impact share value. However, pending regulatory approvals and unpredictable market demand pose risks that shareholders must monitor closely.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information herein is based on official company disclosures and may be subject to change based on regulatory, market, or corporate developments.

View ETHK LABS INC. Historical chart here